5/13/2025
Last update
5/13/2025
Reviewed By
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 5 Researches
7.4
USERS' SCORE
Good
Based on 22 Reviews
8.4
Supplement Facts
Serving Size: 1 Veggie Capsule
Serving Per Container: 60
Amount Per Serving
%DV
Vitamin K2 (from MenaQ7® Menaquinone, MK-7)
45 mcg
38%
Top Medical Research Studies
7
We examined the effectiveness and safety of vitamin K antagonists (VKAs) in resolving left ventricular thrombosis in a group of 90 patients over 12 months.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
Read More
7
VKAs show limited effectiveness in AF
We evaluated the effectiveness of vitamin K antagonists (VKAs) in patients with both valvular and nonvalvular atrial fibrillation. Over an average follow-up of 17 months involving 1,350 patients, we found that the annual incidence of thromboembolic events and cardiovascular death was 4.4%. However, prior thromboembolism and bleeding, along with factors like kidney function and left atrial size, emerged as significant predictors of adverse clinical outcomes. Importantly, VKAs demonstrated limited benefits, as the overall findings highlighted more risk factors than significant treatment advantages.
Read More
7
Anticoagulant treatment effectiveness assessment
We explored the effectiveness of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation post-mitral valve transcatheter edge-to-edge repair (M-TEER). Our analysis included data from 206 patients, and we found that the incidence of serious events was similar between the two groups, indicating no significant benefit for either treatment. However, VKAs were linked to higher overall mortality. These findings suggest that while DOACs and VKAs may be similarly effective in preventing thromboembolic incidents, VKAs could pose greater risks for death.
Read More
Most Useful Reviews
9
Improved health benefits
2 people found this helpful
One, it supports cardiovascular health. Two, it protects against osteoporosis. Three, it fights inflammation. Four, it helps maintain the skin's youthfulness and health, which is crucial. Five, it reduces the risk of oncological diseases. Six, it increases endurance.
Read More
9
Supports bone health
1 people found this helpful
I take Vitamin K2 alongside Vitamin D3 5000 IU. They work together to support both bone and cardiovascular health while aiding in the maintenance of healthy calcium levels.
Read More
9
Prevents vascular calcification
1 people found this helpful
I take Doctor's Best, Natural Vitamin K2 MK-7 daily with Vitamin D3. It directs calcium to the bones, preventing vascular calcification and reducing the risk of cardiovascular disease while also minimising osteoporosis risk.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 5 Researches
7.4
- All Researches
9
Impact of renal function on anticoagulation
We explored how kidney function impacts the safety and effectiveness of different anticoagulant therapies in patients with atrial fibrillation. By analyzing data from the GLORIA-AF registry involving over 10,000 patients, we found that better kidney function was linked to lower risks of serious health events.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
Read More
7
We examined the effectiveness and safety of vitamin K antagonists (VKAs) in resolving left ventricular thrombosis in a group of 90 patients over 12 months.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
Read More
7
VKAs show limited effectiveness in AF
We evaluated the effectiveness of vitamin K antagonists (VKAs) in patients with both valvular and nonvalvular atrial fibrillation. Over an average follow-up of 17 months involving 1,350 patients, we found that the annual incidence of thromboembolic events and cardiovascular death was 4.4%. However, prior thromboembolism and bleeding, along with factors like kidney function and left atrial size, emerged as significant predictors of adverse clinical outcomes. Importantly, VKAs demonstrated limited benefits, as the overall findings highlighted more risk factors than significant treatment advantages.
Read More
7
Anticoagulant treatment effectiveness assessment
We explored the effectiveness of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation post-mitral valve transcatheter edge-to-edge repair (M-TEER). Our analysis included data from 206 patients, and we found that the incidence of serious events was similar between the two groups, indicating no significant benefit for either treatment. However, VKAs were linked to higher overall mortality. These findings suggest that while DOACs and VKAs may be similarly effective in preventing thromboembolic incidents, VKAs could pose greater risks for death.
Read More
7
Atrial fibrillation treatment effectiveness confirmed
We explored how closely real-world patients with atrial fibrillation matched the results from major trials using apixaban and rivaroxaban compared to vitamin K antagonists. By tracking patients from the GARFIELD-AF registry, we observed that these real-life outcomes on stroke prevention, bleeding, and mortality closely mirrored those of the original trials. The study found that while the real-world patients had lower cardiovascular risks, the efficacy and safety of the treatments remained strong and comparable. This demonstrates that the findings from the ARISTOTLE and ROCKET AF trials are relevant in everyday clinical settings.
Read More
User Reviews
USERS' SCORE
Good
Based on 22 Reviews
8.4
- All Reviews
- Positive Reviews
- Negative Reviews
9
Improved health benefits
2 people found this helpful
One, it supports cardiovascular health. Two, it protects against osteoporosis. Three, it fights inflammation. Four, it helps maintain the skin's youthfulness and health, which is crucial. Five, it reduces the risk of oncological diseases. Six, it increases endurance.
Read More
9
Supports bone health
1 people found this helpful
I take Vitamin K2 alongside Vitamin D3 5000 IU. They work together to support both bone and cardiovascular health while aiding in the maintenance of healthy calcium levels.
Read More
9
Prevents vascular calcification
1 people found this helpful
I take Doctor's Best, Natural Vitamin K2 MK-7 daily with Vitamin D3. It directs calcium to the bones, preventing vascular calcification and reducing the risk of cardiovascular disease while also minimising osteoporosis risk.
Read More
9
Cardiovascular benefits
A great product with quality ingredients and high dosage, providing significant cardiovascular benefits.
Read More
9
Blood clotting support
Menaquinone-7, a type of Vitamin K2, is essential for blood clotting and promotes bone health. A deficiency is linked to chronic diseases, including cardiovascular disease.
Read More
Frequently Asked Questions
9
Reversed gum disease
6 people found this helpful
Taking this vitamin with D3 was miraculous for my periodontal health! My dentist was astonished by the results. After starting the supplement to combat worsening conditions from perimenopause, I noticed stopped tartar growth and improved gum condition within just two months. I hope sharing my experience helps others prevent tooth loss!
9
Supports cardiovascular health
1 people found this helpful
An excellent choice for bone and cardiovascular health. This product features high-quality vitamin K2 MK-7, which optimises calcium levels in bones while preventing its accumulation in blood vessels. I noticed improvements in both bone and heart health after regular use.
9
Improved health benefits
2 people found this helpful
One, it supports cardiovascular health. Two, it protects against osteoporosis. Three, it fights inflammation. Four, it helps maintain the skin's youthfulness and health, which is crucial. Five, it reduces the risk of oncological diseases. Six, it increases endurance.
8
Supports bone health
29 people found this helpful
Fantastic help for my bones. As a naturopath, I believe this is essential for anyone wishing to maintain healthy bones and a strong cardiovascular system. The science supports its effectiveness in slowing bone loss, enhancing regrowth, and restoring elasticity to veins and arteries!
9
Prevents vascular calcification
1 people found this helpful
I take Doctor's Best, Natural Vitamin K2 MK-7 daily with Vitamin D3. It directs calcium to the bones, preventing vascular calcification and reducing the risk of cardiovascular disease while also minimising osteoporosis risk.
7.5
Protects against heart disease
1 people found this helpful
Vitamin K2 helps redistribute calcium, removing it from arteries. Excess calcium can make vessels fragile and contribute to cardiovascular disease. K2 acts as a protector against heart attacks. Stay healthy!
8
Bone calcium absorption
6 people found this helpful
I take it daily with Vitamin D3. Research shows that together they ensure calcium from Vitamin D is absorbed into bones. The tiny soft gels are easy to swallow, and the Menaquinone-7 form of Vitamin K-2 is highly effective. K2 aids in redirecting calcium to bones, which is crucial for vascular health and inflammation.
6
Maintains vascular health
1 people found this helpful
I chose this product for quality and value. MK7 is potent, remaining active longer in the body. K2 enhances calcium absorption and helps clean calcium deposits from blood vessels, slowing aging and reducing risks of cardiovascular disease. Remember to take it with food for better absorption. I recommend it with calcium and vitamin D for optimal benefits!
9
Supports bone health
1 people found this helpful
I take Vitamin K2 alongside Vitamin D3 5000 IU. They work together to support both bone and cardiovascular health while aiding in the maintenance of healthy calcium levels.
9
Potential lifespan extension
1 people found this helpful
Vitamin K2 may enhance lifespan. Those with higher doses had a significantly lower risk of dying from coronary heart disease and experienced less arterial calcification. Many, including myself, may require supplements to remedy deficiencies that adversely affect our bones and cardiovascular health.
7
VKAs show limited effectiveness in AF
We evaluated the effectiveness of vitamin K antagonists (VKAs) in patients with both valvular and nonvalvular atrial fibrillation. Over an average follow-up of 17 months involving 1,350 patients, we found that the annual incidence of thromboembolic events and cardiovascular death was 4.4%. However, prior thromboembolism and bleeding, along with factors like kidney function and left atrial size, emerged as significant predictors of adverse clinical outcomes. Importantly, VKAs demonstrated limited benefits, as the overall findings highlighted more risk factors than significant treatment advantages.
7
Anticoagulant treatment effectiveness assessment
We explored the effectiveness of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation post-mitral valve transcatheter edge-to-edge repair (M-TEER). Our analysis included data from 206 patients, and we found that the incidence of serious events was similar between the two groups, indicating no significant benefit for either treatment. However, VKAs were linked to higher overall mortality. These findings suggest that while DOACs and VKAs may be similarly effective in preventing thromboembolic incidents, VKAs could pose greater risks for death.
7
We examined the effectiveness and safety of vitamin K antagonists (VKAs) in resolving left ventricular thrombosis in a group of 90 patients over 12 months.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
9
Impact of renal function on anticoagulation
We explored how kidney function impacts the safety and effectiveness of different anticoagulant therapies in patients with atrial fibrillation. By analyzing data from the GLORIA-AF registry involving over 10,000 patients, we found that better kidney function was linked to lower risks of serious health events.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
References
- Valeriani E, Astorri G, Pannunzio A, Pastori D, Palumbo IM, et al. Long-term left ventricular thrombosis resolution in patients receiving vitamin k antagonists: a multicenter observational study. Intern Emerg Med. 2025. 10.1007/s11739-025-03922-6
- Liporace IL, Oliveira GBF, Alves LBO, Galassi NM, Jeronimo AD, et al. Incidence and Predictors of Clinical Outcomes in Patients with Valvular and Nonvalvular Atrial Fibrillation Using Vitamin K Antagonists. Arq Bras Cardiol. 2025;122:e20240147. 10.36660/abc.20240147
- Liu Y, Lam SHM, Romiti GF, Huang B, Chen Y, et al. Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III. J Thromb Thrombolysis. 2025;58:165. 10.1007/s11239-025-03067-5
- Schipper JH, Sommer AS, Nies RJ, Metze C, Meertens MM, et al. Direct Oral Anticoagulants Versus Vitamin K Antagonists After Mitral Valve Transcatheter Edge-to-Edge Repair in Patients With Atrial Fibrillation: A Single-Center Observational Study. J Am Heart Assoc. 2025;14:e038834. 10.1161/JAHA.124.038834
- Himmelreich JCL, Virdone S, Camm AJ, Pieper K, Harskamp RE, et al. Emulation of ARISTOTLE and ROCKET AF trials in real-world atrial fibrillation patients results in similar efficacy and safety as original landmark trials: insights from the GARFIELD-AF registry. Open Heart. 2025;12. 10.1136/openhrt-2024-002966
